Haemonetics (NYSE:HAE - Get Free Report) had its price target dropped by Needham & Company LLC from $108.00 to $104.00 in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. The brokerage presently has a "buy" rating on the medical instruments supplier's stock. Needham & Company LLC's price objective would suggest a potential upside of 62.30% from the stock's current price.
A number of other analysts have also weighed in on the stock. JMP Securities reduced their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research note on Friday, February 7th. JPMorgan Chase & Co. initiated coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an "overweight" rating and a $116.00 target price on the stock. Barrington Research dropped their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. StockNews.com downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Saturday, February 15th. Finally, Raymond James reiterated a "strong-buy" rating and issued a $115.00 target price (down from $120.00) on shares of Haemonetics in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Haemonetics presently has an average rating of "Moderate Buy" and an average price target of $101.22.
Read Our Latest Stock Analysis on HAE
Haemonetics Stock Performance
Shares of NYSE HAE traded down $0.16 during midday trading on Tuesday, hitting $64.08. The company's stock had a trading volume of 887,916 shares, compared to its average volume of 649,971. Haemonetics has a 1-year low of $58.80 and a 1-year high of $97.97. The firm's fifty day moving average price is $67.29 and its 200-day moving average price is $75.03. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The firm has a market cap of $3.22 billion, a P/E ratio of 25.23, a P/E/G ratio of 1.11 and a beta of 0.43.
Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, sell-side analysts forecast that Haemonetics will post 4.55 EPS for the current fiscal year.
Institutional Trading of Haemonetics
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC grew its stake in shares of Haemonetics by 206.3% in the third quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier's stock valued at $62,257,000 after buying an additional 521,640 shares in the last quarter. Norges Bank bought a new position in shares of Haemonetics in the fourth quarter valued at $32,803,000. Wellington Management Group LLP grew its stake in shares of Haemonetics by 9.5% in the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier's stock valued at $337,722,000 after buying an additional 363,702 shares in the last quarter. Voya Investment Management LLC grew its stake in shares of Haemonetics by 820.5% in the fourth quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier's stock valued at $24,748,000 after buying an additional 282,521 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Haemonetics by 434.8% during the fourth quarter. The Manufacturers Life Insurance Company now owns 314,067 shares of the medical instruments supplier's stock worth $24,522,000 after purchasing an additional 255,338 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.
Haemonetics Company Profile
(
Get Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Read More
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
